EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
Galderma Group AG Registered Shares GALD
News
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
/C O R R E C T I O N — Cetaphil/
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
Galderma Raises 2026 Sales Guidance on Strong Growth
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns
Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S. — Update
Galderma Shares Fall After Bid to Launch Botox Rival in U.S. Hits FDA Setback
Galderma Application for Product to Rival Botox Turned Down Again by FDA
Galderma Shares Gain After Sales Increase, Confidence on Outlook
L'Oreal Doubles Stake in Swiss Skincare Company Galderma — Update
L'Oreal Doubles Stake in Swiss Skincare Company Galderma
Galderma Shares Rise After Guidance Lift
United States